Congenital IRF5 deficiency induces the upregulation of IRF4 in DCs followed by an augmented IL-23 production from DCs, resulting in the amplification of Th17 responses and the exacerbation of imiquimod-induced psoriasis-like skin inflammation. This evidence concerns the gene IRF4 and dermatitis.